Humacyte (HUMA, $4.39) was one of top quarterly gainers, jumping +2 to $4.39 per share. A.I.dvisor analyzed 915 stocks in the Biotechnology Industry over the last three months, and discovered that of them (4) charted an Uptrend while of them (5) trended down. A.I.dvisor found 81 similar cases when HUMA's price went up within three months. In out of those 81 cases, HUMA's price went down during the following month. Based on these historical data, A.I. thinks the odds of an Uptrend reversal for HUMA are